In particular, our data strongly support that the PDTC subtype—as defined by Turin consensus criteria—is separate even molecularly from the other high-grade differentiated thyroid cancers, mainly because of the high prevalence of NRAS mutations and the extremely low prevalence of BRAF mutations [10, 26, 27]. The gene discussed is NRAS; the disease is differentiated thyroid carcinoma.